Abstract
Continuing our studies on the structure-activity relationships (SAR) of 4-iodo-1-beta-D-ribofuranosyl-3-carboxymethyl pyrazole (IPCAR), the ribofuranosyl moiety has been substituted with acyclic chains, namely 1-[(2-hydroxyethoxy)methyl]- and 1-[(1,3-dihydroxy-2-propoxy)methyl]-pyrazole derivatives (4, 5 and 8, 9 respectively), with the 2'-deoxy-beta-D-ribofuranosyl group (12 and 13) and finally with the 2',3'-dideoxy-D-glycero-pentofuranosyl-moiety (16 and 17). None of the new compounds display any interesting biological activity.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antineoplastic Agents / chemical synthesis
-
Antineoplastic Agents / pharmacology
-
Antiviral Agents / chemical synthesis
-
Antiviral Agents / pharmacology
-
Bacteria / drug effects
-
HIV-1 / drug effects
-
Humans
-
Nucleosides / chemical synthesis*
-
Nucleosides / pharmacology*
-
Pyrazoles / chemical synthesis*
-
Pyrazoles / pharmacology*
-
Structure-Activity Relationship
-
Tumor Cells, Cultured / drug effects
-
Yeasts / drug effects
Substances
-
4-iodo-1-ribofuranosyl-3-carboxymethyl pyrazole
-
Antineoplastic Agents
-
Antiviral Agents
-
Nucleosides
-
Pyrazoles